Pfizer readies to compete against Ascendis and Novo Nordisk: Submits weekly growth hormone to FDA
The US FDA has started processing a week-based growth hormone from partners Pfizer and Opko, which will compete against new drugs from Novo Nordisk and Ascendis.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical companies Novo Nordisk and Ascendis have renewed competition to look forward to in the market for treating dwarfism.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EU to help vaccine manufacturers expand production
For subscribers
Ascendis submits FDA application to start cancer trial
For subscribers
.jpg)
.jpg&w=384&q=75)
